Forxiga - direct healthcare professional communication (DHPC)

dapagliflozin propanediol monohydrate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus

Key facts

• Medicine name:
  Forxiga
• Active substance:
  dapagliflozin propanediol monohydrate
• Therapeutic area (MeSH):
  Diabetes Mellitus, Type 2
• Procedure number:
  EMEA/H/C/002322/II/0071
• Regulatory outcome:
  Variation
• DHPC type:
  Type II variation
• Human ATC codes:
  A10BK01
• Dissemination date:
  11/11/2021